I. COMMENCED TRADING IN JUNE | ||||||||
Company (Symbol) |
Date Filed |
Date Comm. |
Shares/ |
Price |
Shares Out (M) |
Lead, Other Underwriters |
Gross (M) |
Post-Offering Market Cap (M) |
| | ||||||||
INITIAL OFFERINGS | ||||||||
There were no initial public offerings conducted in June. | ||||||||
| ||||||||
Total: $0M | ||||||||
Number of IPOs in June: 0 | ||||||||
Average value of June IPOs: $0M | ||||||||
Number of IPOs in 2003: 0 | ||||||||
Total raised in IPOs in 2003: $0M | ||||||||
Average value of IPOs in 2003: $0M | ||||||||
FOLLOW-ON OFFERINGS | ||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/ |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (M) |
Post-Offering Market Cap (M)% |
| | ||||||||
Cerus Corp. (CERS)1 |
8/13/01 |
6/6/03 |
6S |
$9.63 |
22 |
Morgan Stanley |
$57.78 |
$211.86 |
|
||||||||
Exelixis Inc. (EXEL)2 |
7/30/01 |
6/20/03 |
10S |
$7.10 |
69.9 |
Goldman, Sachs (co-lead) SG Cowen Securities |
$71 |
$496.29 |
|
||||||||
Lorus Therapeutics Inc. (Canada; OTC BB: LORFF; TSE:LOR)3 |
5/28/03 |
6/11/03 |
22.8U |
C$1.25 |
N/A |
Loewen, Ondaatje, McCut. Dundee Securities Harris Partners Haywood Securities |
C$32.8 (US$24.4) |
N/A |
|
||||||||
Total: $153.18M | ||||||||
Number of follow-on offerings in June: 3 | ||||||||
Average value of June follow-ons: $51.06M | ||||||||
Number of follow-on offerings in 2003: 13 | ||||||||
Total raised in follow-ons in 2003: $780.34M | ||||||||
Average value of follow-ons in 2003: $60.03M | ||||||||
|
| ||||||||
Notes: | ||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||||
% Market capitalization calculated is based on the offering price; N/A = Not available. | ||||||||
OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||||||
1. Cerus raised $57.78M in a public offering. The underwriter has an overallotment option on 900,000 shares. | ||||||||
2. Exelixis sold 10M shares at $7.10 each, raising $71M. The underwriters have an option to purchase up to an additional 1.5M shares. | ||||||||
3. Lorus raised US$21.1M after completing an offering for 22.8M units, each consisting of one common share and one-half of one common share purchase warrant. The underwriters also exercised their full overallotment option of 3.42M units, raising additional gross proceeds of C$4.275M (US$3.17M) | ||||||||
| ||||||||
II. FILED AND PENDING | ||||||
Company (Symbol/ Proposed Symbol)#* |
Date Filed |
Shares/ |
Price Range |
Shares Out (M)@ |
Lead, Other Underwriters |
Value (M) |
INITIAL OFFERINGS | ||||||
ViaCell Inc. |
1/30/02 |
N/A |
N/A |
N/A |
UBS Warburg Banc of America Securities U.S. Bancorp Piper Jaffray |
$115 |
FOLLOW-ON OFFERINGS | ||||||
Alteon Inc. (AMEX:ALT)2 |
6/13/03 |
N/A |
N/A |
N/A |
N/A |
$100 |
|
||||||
Biomira Inc. |
5/2/02 |
N/A |
N/A |
53.4 |
N/A |
C$150 (US$97.84) |
|
||||||
BioPure Corp. |
3/6/03 |
N/A |
N/A |
N/A |
N/A |
$20.47 |
|
||||||
Celgene Corp. |
12/21/01 |
N/A |
N/A |
75.6 |
N/A |
$500 |
|
||||||
Cell Genesys Inc. |
12/23/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
|
||||||
Cell Pathways |
2/7/01 |
N/A |
N/A |
N/A |
N/A |
$25 |
|
||||||
Centrex Inc. |
2/24/03 |
N/A |
N/A |
N/A |
HD Brous & |
$20 |
|
||||||
Cepheid Inc. |
12/21/01 |
N/A |
N/A |
26.56 |
N/A |
$35 |
|
||||||
Cubist |
3/7/03 |
N/A |
N/A |
N/A |
N/A |
$75 |
|
||||||
Dendreon Corp. |
1/22/03 |
N/A |
N/A |
N/A |
N/A |
$75 |
|
||||||
GenVec Inc. |
12/19/02 |
N/A |
N/A |
N/A |
N/A |
$25 |
|
||||||
Geron Corp. |
1/30/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
|
||||||
Hemispherx |
1/15/03 |
5S |
$2.16 |
37.6 |
N/A |
$10.8 |
|
||||||
InSite Vision |
2/2/01 |
N/A |
N/A |
N/A |
Ladenburg Thalmann (placement agent) |
$40 |
|
||||||
Lexicon Genetics |
11/27/02 |
12S |
$3.98 |
N/A |
N/A |
$47.76 |
|
||||||
MGI Pharma |
6/17/03 |
N/A |
N/A |
N/A |
N/A |
$150 |
|
||||||
Neose |
6/23/03 |
N/A |
N/A |
N/A |
N/A |
$75 |
|
||||||
Neurocrine Biosciences Inc. |
6/9/03 |
N/A |
N/A |
N/A |
N/A |
$200 |
|
||||||
Neurogen Corp. |
8/16/02 |
N/A |
N/A |
N/A |
N/A |
$75 |
|
||||||
Northfield |
6/30/03 |
N/A |
N/A |
N/A |
N/A |
$50 |
|
||||||
Onyx |
6/13/03 |
N/A |
N/A |
N/A |
N/A |
$75 |
|
||||||
Pharmos Corp. |
2/4/02 |
N/A |
N/A |
56.6 |
N/A |
$25 |
|
||||||
StemCells Inc. |
3/8/02 |
15S |
$2.52 |
25.8 |
N/A |
$37.8 |
|
||||||
Tularik Inc. |
8/14/01 |
N/A |
N/A |
49.2 |
N/A |
$250 |
|
||||||
VaxGen Inc. |
11/7/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
|
||||||
Vicuron |
6/9/03 |
N/A |
N/A |
N/A |
N/A |
$70 |
|
||||||
III. WITHDRAWN AND POSTPONED | ||||||
Company (Symbol/ Proposed Symbol)#* |
Date Filed/ Date Pulled |
Shares/ |
Price Range |
Shares Out (M) |
Lead, Other |
Value (M) |
| | ||||||
FOLLOW-ON OFFERINGS | ||||||
ICOS Corp. |
5/28/03 6/18/03 |
N/A |
N/A |
N/A |
N/A |
$150 |
|
| ||||||
Notes: | ||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||
* Stock symbols for companies seeking to complete IPOs are proposed. | ||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||
N/A = Not available, applicable or reported. | ||||||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||||
1. ViaCell filed for a $115M IPO. No further details were disclosed. | ||||||
2. Alteon filed a shelf registration statement to offer and sell, from time to time, up to $100M of securities. | ||||||
3. Biomira filed for a $150M shelf prospectus in Canada. The company raised US$3.7M in a private placement in May. | ||||||
4. BioPure registered to sell up to 10M shares of common stock through a shelf registration. Based on the March 6, 2003, closing stock price of $3.84, the offering would raise $38.4M. Biopure raised $7.3M in private placements conducted in May. | ||||||
5. Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M. In May, Celgene privately placed $400M in convertible notes. | ||||||
6. Cell Genesys filed a shelf registration statement allowing it to issue, from time to time, up to $150M of securities. | ||||||
7. Cell Pathways filed a shelf registration statement for the sale of $25M in common stock. The company privately placed $4.4M in shares in September 2002. | ||||||
8. Centrex plans to raise $20M with HD Brous as its managing underwriter. | ||||||
9. Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants. Company privately placed $5M in stock in February. | ||||||
10. Cubist filed a shelf registration statement to sell up to $75M in stock. | ||||||
11. Dendreon filed a shelf registration with the SEC to sell $75M in stock from time to time. Dendreon raised $30.7M in a private placement in June. | ||||||
12. GenVec filed a $25M shelf registration statement with the SEC. | ||||||
13. Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants. Geron raised $18.4M in a private placement in April. | ||||||
14. Hemispherx filed to register 5M shares of common stock. The value, $10.8M, is based on the proposed maximum offering price. The company privately placed $5.5M in senior convertible debentures and warrants in March. | ||||||
15. InSite filed a shelf registration statement in February 2001 to sell $40M in stock. | ||||||
16. Lexicon Genetics filed a shelf registration statement with the SEC to sell up to an aggregate of 12M shares of common stock from time to time. The value, $47.76M, is based on the proposed maximum aggregate offering price per share, $3.98. | ||||||
17. MGI Pharma filed a shelf registration statement allowing it to sell common stock, preferred stock, debt securities, convertible debt securities and securities warrants up to a total value of $150M. | ||||||
18. Neose filed a shelf registration statement to offer and sell up to $75M of its common stock from time to time. | ||||||
19. Neurocrine filed a $200M shelf registration statement. | ||||||
20. Neurogen filed for a $75M universal shelf registration statement. | ||||||
21. Northfield filed a shelf registration statement with the SEC to offer and sell up to $50M of its securities from time to time. | ||||||
22. Onyx filed a registration statement to sell up to $75M in common stock. | ||||||
23. Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants. The company raised $4.3M in a private placement in March. | ||||||
24. StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed. The company privately placed $6.5M in shares in May. | ||||||
25. Tularik filed to sell up to $250M in common stock and debt securities. It raised $27.2M in October 2002 with an offering of 4M shares. As of May 2003, $217.8M remained available on the registration statement. | ||||||
26. VaxGen filed a shelf registration statement for $150M in common stock, preferred stock, debt securities and warrants. Further details were not disclosed. It privately placed $5M in stock in May, and $7M in June. | ||||||
27. Vicuron filed a shelf registration to offer and sell up to $70M of its shares from time to time. | ||||||
28. ICOS withdrew its shelf registration statement saying it no longer plans to pursue such a financing following the pricing of a private offering in June. | ||||||